Ainos advances innocations with AI Nose, VELDONA technologies

Ainos continues to push the boundaries of global smart healthcare and immunotherapy innovation. The company said, “With its AI Nose and VELDONA low-dose oral interferon technologies, Ainos is not only spearheading advancements in medical technology but also demonstrating significant potential for industrial safety and automation applications. The Company’s excellent research and development progress aligns with its strategic plans, with certain projects being completed ahead of schedule, showcasing Ainos’ exceptional ability in both technology deployment and commercialization…Ainos has cemented its leadership in the fields of smart healthcare and immunotherapy through its dual innovations: AI-powered electronic nose technology and VELDONA low-dose oral interferon. With excellent progress in research and development, and ahead-of-schedule project completion, the Company continues to demonstrate its technological prowess. Moving forward, Ainos plans to expand the application of its technologies, playing a key role in driving global advancements in smart healthcare and industrial automation.”